{"filing":{"accession_number":"0000872589-26-000023","cik":"0000872589","ticker":"REGN","company_name":"REGENERON PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"regn-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/regn-20260730.htm"},"events":[{"id":21979,"run_id":19848,"accession_number":"0000872589-26-000023","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"summary":"This is a clear earnings release disclosing Regeneron's financial and operating results for Q2 2026. The press release, furnished as Exhibit 99.1 to Item 2.02, reports quarterly revenues of $4.3 billion (17% increase), GAAP EPS of $12.23, non-GAAP EPS of $14.29, and provides detailed product sales performance and 2026 financial guidance. This is a standard quarterly earnings disclosure material to investors.","company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21772,"accession_number":"0000872589-26-000023","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"reasoning":"This is a clear earnings release disclosing Regeneron's financial and operating results for Q2 2026. The press release, furnished as Exhibit 99.1 to Item 2.02, reports quarterly revenues of $4.3 billion (17% increase), GAAP EPS of $12.23, non-GAAP EPS of $14.29, and provides detailed product sales performance and 2026 financial guidance. This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:49:45.602794+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21772,"accession_number":"0000872589-26-000023","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"reasoning":"This is a clear earnings release disclosing Regeneron's financial and operating results for Q2 2026. The press release, furnished as Exhibit 99.1 to Item 2.02, reports quarterly revenues of $4.3 billion (17% increase), GAAP EPS of $12.23, non-GAAP EPS of $14.29, and provides detailed product sales performance and 2026 financial guidance. This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:49:45.602794+00:00","company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","filing_date":"2026-07-30"}]}